Literature DB >> 1119711

Anesthetic biotransformation and renal function in obese patients during and after methoxyflurane or halothane anesthesia.

S R Young, R K Stoelting, C Peterson, J A Madura.   

Abstract

Anesthetic biotransformation and renal function were studied in obese adult patients (148 plus or minus 8 kg; mean plus or minus SE) anesthetized for three hours with 60 per cent nitrous oxide plus either methoxyflurane or halothane for elective jejunoileal small-bowel-bypass operations. There was no evidence of persistent renal dysfunction in any patient postoperatively, but serum osmolality was elevated 72 hours after methoxyflurane anesthesia. Urine concentrating ability was not determined. Peak serum ionic fluoride concentration was 55.8 plus or minus 5.8 muM/1 two hours after discontinuation of methoxyflurane. Urinary ionic fluoride and oxalate excretions increased postoperatively. Compared with previously reported data from nonobese patients, serum ionic fluoride concentrations in obese patients increased more rapidly during methoxyflurane anesthesia and peaked higher and sooner after discontinuation of methoxyflurane. The peak serum ionic fluoride concentration was 10.4 plus or minus 1.5 muM/1 at the conclusion of halothane anesthesia, significantly more than the corresponding value in nonobese patients. Intraoperative liver biopsies from 23 of 27 patients showed moderate to severe fatty metamorphosis. Fatty liver infiltration may have increased hepatic anesthetic uptake and exposed more methoxyflurane or halothane to hepatic microsomal enzymes. The more rapid elevation and higher peak levels of serum ionic fluoride following methoxyflurane, and to a lesser extent following halothane, may reflect increased anesthetic biotransformation in obese compared with nonobese patients. To avoid excessive serum ionic fluoride elevations the authors recommended limiting low-dose methoxyflurane anesthesia delivered to obese patients with potential fatty liver infiltration to no more than three hours.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1119711     DOI: 10.1097/00000542-197504000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

2.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

3.  In vitro effects of fluoride and bromide on pseudocholinesterase and acetylcholinesterase activities.

Authors:  J R Kambam; W C Parris; R J Naukam; J J Franks; B V Sastry
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

Review 4.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

5.  Toxicity following methoxyflurane anaesthesia. IV. The role of obesity and the effect of low dose anaesthesia on fluoride metabolism and renal function.

Authors:  P N Samuelson; R G Merin; D R Taves; R B Freeman; J F Calimlim; T Kumazawa
Journal:  Can Anaesth Soc J       Date:  1976-09

6.  Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia.

Authors:  Y Tohyama
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

7.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.